Phase 2 Study of EPI-743 for Treatment of Rett Syndrome
Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
Rett syndrome is a severe neurodevelopmental disorder that primarily affects female children.
Rett syndrome is characterized by significant elevation in blood markers of oxidative stress.
EPI-743 is a novel therapeutic with demonstrated efficacy and safety in the treatment of
disorders characterized by oxidative stress. The purpose of this study is to examine the
safety and efficacy of EPI-743 in a population of children with Rett syndrome.